Management of Severe Asthma: Summary of the European Respiratory Society/American Thoracic Society Task Force Report

Overview

Journal Breathe (Sheff)

Specialty Pulmonary Medicine

Date 2020 Dec 11

PMID 33304407

Citations 7

Authors

Sandhya Khurana

Andrew Bush

Fernando Holguin

Affiliations

Soon will be listed here.

Abstract

This article is mainly intended for trainees and specialists who are interested in the management of severe asthma. It aims to inform readers about the updated ERS/ATS recommendations for management of severe asthma, specifically on the topics of biologics, macrolides and long-acting muscarinic antagonists.It also provides guidance on utilisation of available biomarkers in selecting advanced therapies in severe asthma.

Citing Articles

Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment.

DAiuto V, Mormile I, Granata F, Romano A, Della Casa F, Mignogna G Int J Mol Sci. 2025; 26(4).

PMID: 40004192 PMC: 11855446. DOI: 10.3390/ijms26041729.

Altered control of breathing in a rat model of allergic lower airway inflammation.

Morgan B, Song R, McDermott I, Brinkman J, Holbert K, Oler A J Neurophysiol. 2024; 132(5):1650-1666.

PMID: 39382982 PMC: 11573259. DOI: 10.1152/jn.00301.2023.

Update on Inflammatory Biomarkers for Defining Asthma Phenotype.

Sim S, Choi Y, Park H Allergy Asthma Immunol Res. 2024; 16(5):462-472.

PMID: 39363766 PMC: 11450439. DOI: 10.4168/aair.2024.16.5.462.

Impact of biological therapies on laboratory outcomes and FEV1 in patients with severe eosinophilic asthma with chronic rhinosinusitis: a real-life study from Saudi Arabia.

Abu Elhassan U, Al-Mani S, Alqahtani S, Elnamaky M, Alfaifi A, Alshehri M Multidiscip Respir Med. 2024; 19.

PMID: 39250180 PMC: 11414510. DOI: 10.5826/mrm.2024.985.

Outcomes of biological therapy in patients with severe asthma with chronic rhinosinusitis in Saudi Arabia: patients with nasal polyps versus those without nasal polyps.

Abuelhassan U, Elnamaky M, Alfifi A, Kadasah S, Alshehri M, Alasiri H BMC Pulm Med. 2024; 24(1):328.

PMID: 38978039 PMC: 11232303. DOI: 10.1186/s12890-024-03139-x.

References

Nair P, Wenzel S, Rabe K, Bourdin A, Lugogo N, Kuna P . Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017; 376(25):2448-2458. DOI: 10.1056/NEJMoa1703501. View

Park H, Kim M, Imai N, Nakanishi T, Adachi M, Ohta K . A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan. Int Arch Allergy Immunol. 2016; 169(3):135-45. DOI: 10.1159/000444799. View

Hamelmann E, Bernstein J, Vandewalker M, Moroni-Zentgraf P, Verri D, Unseld A . A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma. Eur Respir J. 2016; 49(1). PMC: 5298196. DOI: 10.1183/13993003.01100-2016. View

Ortega H, Liu M, Pavord I, Brusselle G, FitzGerald J, Chetta A . Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014; 371(13):1198-207. DOI: 10.1056/NEJMoa1403290. View

Fitzpatrick A, Teague W, Meyers D, Peters S, Li X, Li H . Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol. 2011; 127(2):382-389.e1-13. PMC: 3060668. DOI: 10.1016/j.jaci.2010.11.015. View

Bleecker E, FitzGerald J, Chanez P, Papi A, Weinstein S, Barker P . Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016; 388(10056):2115-2127. DOI: 10.1016/S0140-6736(16)31324-1. View

Szefler S, Murphy K, Harper 3rd T, Boner A, Laki I, Engel M . A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma. J Allergy Clin Immunol. 2017; 140(5):1277-1287. DOI: 10.1016/j.jaci.2017.01.014. View

Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M . Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study. Chest. 2016; 150(4):789-798. DOI: 10.1016/j.chest.2016.03.032. View

Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B . Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016; 388(10039):31-44. DOI: 10.1016/S0140-6736(16)30307-5. View

10.

Castro M, Mathur S, Hargreave F, Boulet L, Xie F, Young J . Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011; 184(10):1125-32. DOI: 10.1164/rccm.201103-0396OC. View

11.

Castro M, Wenzel S, Bleecker E, Pizzichini E, Kuna P, Busse W . Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014; 2(11):879-890. DOI: 10.1016/S2213-2600(14)70201-2. View

12.

Ortega H, Yancey S, Mayer B, Gunsoy N, Keene O, Bleecker E . Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016; 4(7):549-556. DOI: 10.1016/S2213-2600(16)30031-5. View

13.

Kerstjens H, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M . Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012; 367(13):1198-207. DOI: 10.1056/NEJMoa1208606. View

14.

Moore W, Meyers D, Wenzel S, Teague W, Li H, Li X . Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2009; 181(4):315-23. PMC: 2822971. DOI: 10.1164/rccm.200906-0896OC. View

15.

Chupp G, Bradford E, Albers F, Bratton D, Wang-Jairaj J, Nelsen L . Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017; 5(5):390-400. DOI: 10.1016/S2213-2600(17)30125-X. View

16.

Brusselle G, Vanderstichele C, Jordens P, Deman R, Slabbynck H, Ringoet V . Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013; 68(4):322-9. DOI: 10.1136/thoraxjnl-2012-202698. View

17.

Castro M, Corren J, Pavord I, Maspero J, Wenzel S, Rabe K . Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018; 378(26):2486-2496. DOI: 10.1056/NEJMoa1804092. View

18.

Haldar P, Pavord I, Shaw D, Berry M, Thomas M, Brightling C . Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008; 178(3):218-224. PMC: 3992366. DOI: 10.1164/rccm.200711-1754OC. View

19.

Hahn D, Grasmick M, Hetzel S, Yale S . Azithromycin for bronchial asthma in adults: an effectiveness trial. J Am Board Fam Med. 2012; 25(4):442-59. DOI: 10.3122/jabfm.2012.04.110309. View

20.

Sutherland E, King T, Icitovic N, Ameredes B, Bleecker E, Boushey H . A trial of clarithromycin for the treatment of suboptimally controlled asthma. J Allergy Clin Immunol. 2010; 126(4):747-53. PMC: 2950827. DOI: 10.1016/j.jaci.2010.07.024. View